StreetInsider.com News Articles

Cantor Fitzgerald Reiterates Overweight Rating on AbCellera Biologics (ABCL)

Fri, 17 Jul 2026 09:55:57 -0400

Cantor Fitzgerald analyst Steve Seedhouse reiterated an Overweight rating and $11.00 price target on AbCellera Biologics (NASDAQ: ABCL).

The analyst commented, "In 3Q26, ABCL will report Phase 2 data for anti-NK3R antibody ABCL635 in moderate-to-severe vasomotor symptoms (VMS) in menopause, otherwise known as hot flashes. Moderate-to-severe VMS affects >10M women in the U.S. alone every year, symptoms typically last for several years, and the majority of affected women currently don’t seek, are averse to, or are explicitly contraindicated for hormonal therapy...In our view, ABCL635’s Phase 2 data will compare favorably to approved NK3R inhibitors (i.e., better impact on VMS severity, similar

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

Tue, 07 Jul 2026 16:05:00 -0400

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

Tue, 07 Jul 2026 16:05:00 -0400

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

Tue, 07 Jul 2026 16:05:00 -0400

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

Tue, 07 Jul 2026 16:05:00 -0400

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on

Benchmark Upgrades AbCellera Biologics (ABCL) to Buy

Tue, 07 Jul 2026 06:16:07 -0400

Benchmark analyst Robert Wasserman upgraded AbCellera Biologics (NASDAQ: ABCL) from Hold to Buy with a price target of $11.00.

For an analyst ratings summary and ratings history on AbCellera Biologics click here. For more ratings news on AbCellera Biologics click here.

Shares of AbCellera Biologics closed at $7.87 yesterday.

Form 4 AbCellera Biologics Inc. For: Jul 01 Filed by: Seely Lynn

Mon, 06 Jul 2026 18:21:00 -0400

si-local-file:///var/storage/secattach/20260706/26736959.html

Form 4 AbCellera Biologics Inc. For: Jul 01 Filed by: Seely Lynn

Mon, 06 Jul 2026 18:21:00 -0400

si-local-file:///var/storage/secattach/20260706/26736959.html

Form 3 AbCellera Biologics Inc. For: Jun 30 Filed by: Seely Lynn

Mon, 06 Jul 2026 18:15:00 -0400

si-local-file:///var/storage/secattach/20260706/26736936.html

Form 3 AbCellera Biologics Inc. For: Jun 30 Filed by: Seely Lynn

Mon, 06 Jul 2026 18:15:00 -0400

si-local-file:///var/storage/secattach/20260706/26736936.html

Form 4 AbCellera Biologics Inc. For: Jul 01 Filed by: Sandor Victor

Mon, 06 Jul 2026 18:05:00 -0400

si-local-file:///var/storage/secattach/20260706/26736900.html

Form 4 AbCellera Biologics Inc. For: Jul 01 Filed by: Sandor Victor

Mon, 06 Jul 2026 18:05:00 -0400

si-local-file:///var/storage/secattach/20260706/26736900.html

Form 8-K AbCellera Biologics Inc. For: Jun 30

Mon, 06 Jul 2026 14:54:00 -0400

si-local-file:///var/storage/secattach/20260706/26734998.html

Form 8-K AbCellera Biologics Inc. For: Jun 30

Mon, 06 Jul 2026 14:54:00 -0400

si-local-file:///var/storage/secattach/20260706/26734998.html

AbCellera adds Lynn Seely to its board of directors

Mon, 06 Jul 2026 09:00:29 -0400